tirzepatide cvot Comparison of and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics Tirzepatide and Cardiovascular Outcomes: A
Description
Three patients had no identifiable genetic variation associated with chylomicronemia and all were treated with tirzepatide given to maximum tolerated dose
Lancet 358 , 461467 (2001)
Its wider availability in India can be a meaningful step toward improving long-term metabolic health outcomes
Proper use can maximize the medications benefits while reducing the risk of side effects or other problems
